Ozempic (GLP-1 Drugs) Ozempic Blindness Lawsuit
A growing number of lawsuits have been filed against the makers of Ozempic and similar drugs due to severe adverse reactions, including vision loss. If your loved one has developed non-arteritic anterior ischemic optic neuropathy (NAION), a serious eye condition that can lead to sudden, permanent vision loss following treatment with this class of drugs, call our law firm at 800-732-3216.
- Content Reviewed by:
- Rebecca Phillips
- Page Last Updated:
- February 3, 2026
We are actively filing claims against the makers of Ozempic and similar drugs prescribed to treat type 2 diabetes mellitus and obesity. Ozempic is part of a class of drugs known as glucagon peptide-1, or GLP-1, receptor agonists. These drugs mimic the hormone GLP-1, which stimulates insulin production and controls gastric emptying after food is consumed. While Ozempic is the most well-known of these drugs, they are also marketed as Wegovy, Mounjaro, Victoza, Saxenda, and Rybelsus.
Drug manufacturers have a legal duty to provide complete warning labels so doctors and patients can make informed decisions.
Recent research published in JAMA Ophthalmology found that patients treated with these drugs have a higher risk of NAION. The condition occurs due to loss of blood flow to the front of the optic nerve, leading to vision loss in one or both eyes that may be permanent. Contact us now for a free consultation if you or your loved one has been diagnosed with NAION after treatment with this class of drugs.
Ozempic and Vision Loss Lawsuit Updates
Ozempic NAION lawsuits against Novo Nordisk and Eli Lilly allege that the pharmaceutical companies failed to adequately warn of the risk of vision loss or optic neuropathy. While current warning labels list changes in vision as a potential side effect, they do not mention the potential for optic neuropathy. Lawsuits assert that they do not go far enough to warn about the risk of unreasonably dangerous consequences, such as NAION.
December, 2025
The U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated all Ozempic and other GLP-1 blindness lawsuits into a new MDL in the Eastern District of Pennsylvania under U.S. District Judge Karen Marston.
Judge Marston already oversees thousands of gastroparesis lawsuits against Ozempic and other GLP-1 medication makers in a separate MDL established over a year ago. While the two litigation tracks remain separate, the JPML noted significant overlap between the cases, making it efficient for Judge Marston to handle both MDLs since they involve the same attorneys and defendants.
The initial status conference will address case census, applying existing orders from the gastroparesis litigation, selecting lead counsel, and scheduling future conferences, filings, and discovery proceedings.
November, 2025
The New Jersey Supreme Court has consolidated lawsuits alleging injuries from Ozempic and other GLP-1 medications into two separate multicounty litigations (MCLs) under Bergen County Superior Court Judge Gregg A. Padovano. One MCL addresses gastrointestinal injuries, while the other handles Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) vision loss claims, sometimes called an eye stroke.
The cases were filed in New Jersey because Novo Nordisk is based there. Both plaintiff groups requested separate consolidation, noting that while some discovery may overlap, the cases require different expert opinions and evidence. MCLs consolidate similar cases from multiple state courts before one judge for coordinated proceedings.
June 12, 2025
As of June 12, 2025, there were 21 claims filed and pending in Middlesex County, New Jersey, before eight different judges. Plaintiffs have requested a Multicounty designation (“MCL”) to coordinate all these claims. The petition asked that the MCL be limited to NAION injuries only.
The petition states: “Plaintiffs allege Novo Nordisk, Inc. knew or should have known of the risk of NAION and failed to adequately warn of the risks, failed to design a safe product, and failed to conduct adequate testing, including pre-clinical and clinical testing, and post-marketing surveillance to determine the safety of Ozempic and Wegovy.”
Get a Free Legal Consultation
- Passionate legal advocates with decades of trial experience
- Over $20 billion recovered for clients in pharmaceutical liability cases
- No upfront costs or fees
Who Qualifies To File an Ozempic Blindness Lawsuit?
If your loved one has been diagnosed with NAION after using semaglutide, tirzepatide, liraglutide, or other GLP-1 receptor agonists, you may be able to bring a lawsuit.
These drugs were marketed and sold under the following trade names:
- Ozempic
- Wegovy
- Mounjaro
- Victoza
- Saxenda
- Rybelsus
Call 800-723-3216 now to find out how we can help you pursue justice and compensation for your vision loss. Consultations are free.
Rebecca Phillips is dedicated to pharmaceutical liability, business litigation, and appeals. Co-lead counsel in the Bard Implant litigation, she also helped secure billions in opioid recovery for Texas. Recent honors include Super Lawyers Rising Star and Lawdragon 500 (2024-2025), among others.
Contact an Experienced Ozempic Vision Loss Lawyer Today
If your loved one is experiencing vision loss after using Ozempic or similar drugs to treat diabetes or lose weight, you deserve justice. Our experienced lawyers can help. Reach out to us today to learn more.
